| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KIN001-135 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.009 | 0.8 |
| mRNA | BRD-M00053801 | CTRPv2 | pan-cancer | AAC | 0.013 | 0.8 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | ML006 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | AZD4547 | CTRPv2 | pan-cancer | AAC | 0.0098 | 0.8 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.0089 | 0.8 |